Introduction
============

The phosphatase and tensin homolog (PTEN) gene is one of the tumor suppressor genes ([@b1-mco-0-0-1988]) located in chromosome 10q23.31, encoding 403 amino acids of 47166 Da protein. Loss of heterozygosity and deletion of this gene was first reported in glioblastomas, and later in several malignant tumors ([@b2-mco-0-0-1988]). *PTEN* germline mutations cause a wide variety of phenotypic diseases, such as macrocephaly/autism syndrome (OMIM \#605309) usually noticed in infants and *PTEN* hamartoma tumor syndrome (PHTS, OMIM \#601728). PHTS includes Cowden syndrome (CS, OMIM\#158350) and Bannayan-Riley-Ruvalcaba syndrome (BRRS, OMIM\#153480) ([@b3-mco-0-0-1988]).

Macrocephaly/autism syndrome is an autosomal dominant disorder characterized by increased head circumference, abnormal facial features, and delayed psychomotor development resulting in autistic behavior or mental retardation ([@b4-mco-0-0-1988]). Varga *et al* ([@b5-mco-0-0-1988]) reported that *PTEN* mutations were detected in 5 of 60 (8.3%) patients with autism spectrum disorder (ASD) and 6 of 49 (12.2%) patients with developmental delay and macrocephaly without ASD.

CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, and endometrium in young adults and adults. Arteriovenous malformation, multiple lipomas, and other soft-tissue tumors are also reported ([@b3-mco-0-0-1988],[@b6-mco-0-0-1988]). Affected individuals usually develop macrocephaly, trichilemmomas, and papillomatous papules by late 20s. On the other hand, BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis ([@b3-mco-0-0-1988]). For PHTS patients, 2019.2 NCCN guideline ([@b7-mco-0-0-1988]) recommends that tumor follow-up involves annual physical examination and thyroid ultrasound, with colonoscopy every 5 years beginning at age 35 or earlier based on family colon cancer history and kidney ultrasound every 1-2 years starting at age 40.

We found a *de novo PTEN* germline mutation in a male infant with macrocephaly and lipomas by using NGS analysis. A rapidly growing lipoma was resected and examined for *PTEN* by immunostaining, since there have been few reports on PTEN inactivation, two hits or one hit, in tumors in PHTS patients.

Case report
===========

### Patient

Male infant was born after 37 weeks gestation with 4,078 g (+2.7 SD) in weight, 52 cm (+1.4 SD) in height and 36 cm (+1.9 SD) in head circumference.

Family history: No physical abnormalities are apparent with the father, 37 years old, the mother, 33 years old and a sister, 3 years old.

Pregnancy history: Pregnancy progressed uneventfully. The delivery was through the vagina after induction.

Postnatal progress: No special findings in one- and four-month postnatal examinations. The infant showed roll-over at 6 months old, neck stabilization at 7 months old, and independent gait at 1 year and 5 months. He exhibited obsession and temper tantrum frequently after 2 years of age. Macrocephaly was pointed out when he was taken to a hospital for treatment of bronchitis at the age of 8 months. His height was then 70 cm (+2.8 SD), weight 8,845 g (+0.2 SD) and head circumference 48.5 cm (+2.8 SD). Brain MRI showed no abnormal signals in cerebral parenchyma (data not shown), indicating that his macrocephaly was a simple one. To elucidate the cause of macrocephaly, genetic testing was performed at the age of 1 year and 9 months under the informed consents of the parents.

At the age of one-year, two elastic soft subcutaneous tumors of 1-2 cm in diameter appeared in the abdomen and in the right side of the back. A café-au-lait spot of 2 cm in diameter was also found on the left side of the back. At the age of 1 year and 9 months, one tumor in the abdomen rapidly enlarged to 6x5 cm ([Fig. 1A](#f1-mco-0-0-1988){ref-type="fig"}) and was surgically removed. The removed tumor was soft and yellowish and macroscopically diagnosed as a lipoma.

At the age of 2 years and 9 months, the results of genetic testing were reported, and genetic counseling was performed. At this time, his height was 92 cm (+0.2 SD), weight 16 kg (+2.1 SD), and head circumference 55 cm (+3.7 SD). He showed a broad and projected forehead, a flat nasal root and low-set deformed auricles. A café-au-lait spot of 2x2.5 cm in size was present on the left back and subcutaneous tumors of 2x2 cm in the right back ([Fig. 1B](#f1-mco-0-0-1988){ref-type="fig"}) and in the sole (not shown). Developmental test by Kyoto Scale of Psychological Development 2001([@b8-mco-0-0-1988]) showed 64 scores in total developmental quotient (100 as an average), indicating that he had moderate developmental delay.

At the age of 3 years, follow-up brain MRI showed no abnormality in the cerebral white matter ([Fig. 1C](#f1-mco-0-0-1988){ref-type="fig"} and [D](#f1-mco-0-0-1988){ref-type="fig"}), except for the hypertrophied corpus callosum ([Fig. 1E](#f1-mco-0-0-1988){ref-type="fig"}) and enlargement of the perivascular space ([Fig. 1F](#f1-mco-0-0-1988){ref-type="fig"}), of which findings were consistent with simple macrocephaly.

At the age of 5 years, subcutaneous tumors in the back and the sole remained the same in size, and no newly developed tumors and café-au-lait spots were detected. He could not communicate normally and was diagnosed as ASD with moderate developmental delay.

### Chromosomal analysis

Using peripheral blood, G-banding was performed.

### Whole-exome sequencing and Sanger sequencing

DNA was extracted from peripheral blood of the patient and the parents and Whole exome sequencing was performed as previously described ([@b9-mco-0-0-1988]). Regions suspected of containing pathological mutations were amplified by PCR and subjected to Sanger analysis (HGMD^R^ Professional 2016.1).

### Pathologic examination

The surgical specimen was fixed in formalin and embedded in a paraffin block. Sections cut from the block were stained with hematoxylin-eosin and with an immunoperoxidase method using anti-PTEN antibody (Dako/Agilent Technologies, Santa Clara, CA). Stained sections were examined under a light microscope. As a control, a subcutaneous fat containing skin sample obtained from a one-year-old male infant without CS were used anonymously.

### Chromosomal analysis

Chromosomal analysis showed a normal karyotype.

### Mutation of the PTEN gene

In exon 3 of the *PTEN* (NM_000314.7), c.195C\>A, p.Y65^\*^ was found as a heterozygous germline variant in the patient. This mutation is considered as pathogenic, since the same mutation has been reported in one young adult female with macrocephaly/autism syndrome and one adult female with CS ([@b10-mco-0-0-1988],[@b11-mco-0-0-1988]) (referred HGMD^R^ Professional 2019.1). The predicting truncated PTEN protein with deletion of most of the C-terminal region is likely unstable leading to haploinsufficiency. This mutation is sporadic, since his parents did not carry the mutation. Based on these results, we diagnosed this patient with *PTEN* hamartoma tumor syndrome (PHTS). As this mutation was reported in a CS case, we performed ultrasound analysis of the thyroid and visual and palpitation inspection of breasts of the patient at 2 years and 10 months. No abnormalities were found in both tissues. Endoscopic examination of gastrointestinal tract was not performed because of his young age.

### Pathologic findings of the subcutaneous tumor

The surgical specimen had a lobulated macroscopic appearance and was encapsulated with delicate fibrous veil ([Fig. 2A](#f2-mco-0-0-1988){ref-type="fig"}). Histologically, it consisted of mature adipocytes, sparse blood vessels and thin collagen bundles ([Fig. 2B](#f2-mco-0-0-1988){ref-type="fig"}), and the diagnosis of lipoma was confirmed. Immunohistochemically, PTEN expression was observed in vessels in the control sample, as was expected ([Fig. 2C](#f2-mco-0-0-1988){ref-type="fig"} and [D](#f2-mco-0-0-1988){ref-type="fig"}). A few subcutaneous adipocytes were also stained. Similarly, in the lipoma tissue, vessels and a small number of neoplastic adipocytes were PTEN-positive ([Fig. 2E](#f2-mco-0-0-1988){ref-type="fig"} and [F](#f2-mco-0-0-1988){ref-type="fig"}). No obvious differences in PTEN expression, its distribution pattern and intensity, were detected between the lipoma tissue and the control tissue. [Fig. 3](#f3-mco-0-0-1988){ref-type="fig"} shows the position of the mutation in the PTEN protein ([@b12-mco-0-0-1988]). Anti-PTEN antibody binds to a C-terminal region ([@b13-mco-0-0-1988]). It is not possible to bind to the truncated protein due to the nonsense mutation in this patient ([Fig. 3](#f3-mco-0-0-1988){ref-type="fig"}).

Discussion
==========

We found a *PTEN* mutation by NGS analysis in a male infant with macrocephaly. Brain MRI examination showed simple macrocephaly consistent with *PTEN* macrocephaly/autism syndrome reported by Vanderver *et al* ([@b14-mco-0-0-1988]) and Bhargava *et al* ([@b15-mco-0-0-1988]).

[Table I](#tI-mco-0-0-1988){ref-type="table"} shows 30 patients of \<3 years of age with macrocephaly or autism spectrum in whom *PTEN* mutations were detected ([@b4-mco-0-0-1988],[@b11-mco-0-0-1988],[@b14-mco-0-0-1988]). Clinical manifestations of these patients are presented in [Table II](#tII-mco-0-0-1988){ref-type="table"}. All cases showed developmental delay with 8 cases diagnosed as autism spectrum and 10 hypotonia. Ten of 30 cases showed frontal bossing with 8 exhibiting café-au-lait spots and skin features, and 5 diagnosed with tumors and hamartomas, such as gastrointestinal polyps and cutaneous lipomas. Our case, an only in infant patient with macrocephaly/autism syndrome reported, suggests that the *PTEN* mutation detected is responsible for the syndrome.

All the 30 patients with macrocephaly in [Table I](#tI-mco-0-0-1988){ref-type="table"} showed no apparent genotype-phenotype correlation nor malignant tumors that are frequently observed in patients with CS. The risk of developing malignant tumors in later years is not clear, without follow-up data.

Tan *et al* ([@b21-mco-0-0-1988]) reported lifetime cancer risks of individuals with *PTEN* germline mutation listing a variety of cancers (breast, thyroid, endometrial, colorectal, renal cell, and melanoma) found in a cohort of 368 children and adults aged 0.4-83 years (median age; 39 years). The earliest age of cancer onset reported was 3 years for melanoma. In this paper, no follow-up analysis from childhood to adulthood was reported. Consequently, it is not clear as to how many infant macrocephaly cases with *PTEN* mutation developed to CS in adulthood. Smpokou *et al* ([@b22-mco-0-0-1988]) reported that, in the case of a 7-year-old patient with a thyroid cancer, clinical description would allow better formulation of clinical guidelines in children with PHTS. For infant patients with *PTEN* mutation, pediatricians have tendency to focus attention on macrocephaly, developmental delay or autism. It is therefore important to conduct follow-up assessment for both developmental problem and cancer incidence, and carry out lifelong and total medical management.

On this basis, we conducted thyroid ultrasonography of our patient at the age of 2 years and 10 months, 4 years and 5 years of age and found no abnormality. Regarding gastrointestinal tract hamartomas, we did not perform endoscopic examination, since there have been no reports on the onset in childhood. We examined breasts only by inspection and palpation since the possibility of breast cancer was considered to be lower for male infant patients than female ([@b23-mco-0-0-1988]).

Lipomas and a café-au-lait spot on the skin were also found in our case. Our immunohistochemical examination revealed that lipoma tissue and the skin tissue obtained from a control subject showed very similar PTEN expression. No obvious differences in PTEN expression were detected among them, suggesting that two-hit in the PTEN gene by loss of heterozygosity was unlikely even in the rapidly growing lipoma. A previous report shows that loss of heterozygosity of markers in endometrial cancer, glioblastoma, and breast cancer ([@b13-mco-0-0-1988]). In our lipoma case, we are unable to do the immunohistochemical evaluation clearly.

To relieve psychosocial anxiety for PHTS patients and their parents with respect to cancer predisposition and developmental problems, genetic counseling is of need. Genetic counseling is also of use for family members who may feel at risk. Taken together, long-term follow-up plans for soft-tissue tumors, thyroid cancer, breast cancer and GI-hamartomas, as well as psychosocial problems are indispensable.
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![Skin legions and brain MRI of the patient. (A) Appearances on the upper region of the abdomen at the age of 1 year and 9 months. Arrows indicate soft and elastic mass. (B) Appearances on the back at the age of 2 years and 9 months. Arrows indicate a 2x2 cm soft mass in the right side of the back, and an arrowhead indicates a 2x2.5 cm café-au-lait spot on the left side of the back. (C-F) Brain MRI at the age of 3 years. (C) T2 waited axial view. (D) T2 waited axial view upper level than (C). (E) T2 waited sagittal view. Arrows indicate the large corpus callosum, pointing to macrocephaly. (F) T2 waited coronal view. A white arrow indicates the enlarged perivascular spaces with cerebrospinal fluid isointense signals were observed.](mco-12-04-0329-g00){#f1-mco-0-0-1988}

![Pathologic findings of the surgical specimen. (A) Lobulated yellowish tumor encapsulated with delicate fibrous veil. (B) Histologically, the tumor consisted of mature adipocytes, sparse blood vessels and thin collagen bundles. Hematoxylin-eosin stain. Original magnification, x100. (C and D) A control tissue section stained with anti-PTEN antibody. PTEN immunoreactivity was observed in vessels and a few adipocytes. Original magnification, (C) x100 and (D) x400. (E and F) Tumor tissue section stained with anti-PTEN antibody. As seen in the control tissue, PTEN immunoreactivity was observed in both vessels and neoplastic adipocytes. Original magnification, (E) x100 and (F) x400.](mco-12-04-0329-g01){#f2-mco-0-0-1988}

![PTEN protein. p.Y65^\*^ is the position of the mutation in the PTEN protein. PIP2-binding domain (aa 1-13), a catalytic tensin-type phosphatase domain (aa 14-185), a C2 tensin-type domain, which binds phospholipids (aa 190-350), C-terminal tail, the carboxy-terminal tail of the protein (aa 350-400), and a PDZ-binding domain (aa 401-403) are shown ([@b20-mco-0-0-1988]). AB 6H2.1; Anti-PTEN antibody binds to C-terminal 100AA ([@b21-mco-0-0-1988]). Anti-PTEN does not bind to the patients\' protein due to truncation of the binding site. PIP2, phosphatidylinositol 4,5-bisphosphate.](mco-12-04-0329-g02){#f3-mco-0-0-1988}

###### 

Reported 30 patients diagnosed as having PTEN mutation at \<3 years.

  Author, year                                                                           Case no.   Age    *PTEN* mutation                                                                                  Inheritance   (Refs.)
  -------------------------------------------------------------------------------------- ---------- ------ ------------------------------------------------------------------------------------------------ ------------- ---------------------------------------------------------------
  Vanderver *et al*, 2014                                                                1          0d     partial deletion of exon 6, identified on array-CGH; arr10q23.31 (89.683.610-89.702.204) ^\*^1   *de novo*     ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                2          3m     c.1120_1121dup : p.D375^\*^                                                                      *de novo*     ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                3          5m     c.A17T : p.K6I                                                                                   ND            ([@b14-mco-0-0-1988])
  Tan *et al*, 2011 and Vanderver *et al*, 2014                                          4          7m     c.253+5G\>T                                                                                      *de novo*     ([@b11-mco-0-0-1988],[@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                5          7m     Yes                                                                                              ND            ([@b14-mco-0-0-1988])
  Tan *et al*, 2011 and Vanderver *et al*, 2014                                          6          8m     c.T149C : p.I50T                                                                                 *de novo*     ([@b11-mco-0-0-1988],[@b14-mco-0-0-1988])
  Present study                                                                          7          8m     c.C195A : p.Y65^\*^                                                                              *de novo*     \-
  Varga *et al*, 2009                                                                    8          9m     p.R173H                                                                                          Maternal      ([@b5-mco-0-0-1988])
  Varga *et al*, 2009                                                                    9          9m     c.IVS8-2A\>G                                                                                     Paternal      ([@b5-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                10         10m    c.A80G : p.Y27C                                                                                  *de novo*     ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014, Bhargava *et al*, 2014 and Rodríguez-Escudero *et al*, 2011   11         10m    c.G131A : p.G44D                                                                                 ND            ([@b14-mco-0-0-1988],[@b15-mco-0-0-1988],[@b16-mco-0-0-1988])
  Vanderver *et al*, 2014 and Nelen *et al*, 1997                                        12         10m    c.C388T : p.R130^\*^                                                                             ND            ([@b14-mco-0-0-1988],[@b17-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                13         10m    c.C511G : p.Q171E                                                                                Familial      ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014 and Eng, 2003                                                  14         10m    c.C633G : p.C211W                                                                                Familial      ([@b14-mco-0-0-1988],[@b18-mco-0-0-1988])
  Herman *et al*, 2007 and Vanderver *et al*, 2014                                       15         10m    c.C1003T : p.R335^\*^                                                                            *de novo*     ([@b4-mco-0-0-1988],[@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                16         11m    c.A16G : p.K6E                                                                                   ND            ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                17         11m    c.G853T : p.G285^\*^                                                                             *de novo*     ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                18         12m    c\. A320G : p.D107G                                                                              ND            ([@b14-mco-0-0-1988])
  Vanderver *et al*, 2014                                                                19         1y3m   c.C138G : p.Y46^\*^                                                                              ND            ([@b14-mco-0-0-1988])
  Herman *et al*, 2007 and Varga *et al*, 2009                                           20         1y4m   c.520insT                                                                                        *de novo*     ([@b4-mco-0-0-1988],[@b5-mco-0-0-1988])
  Tan *et al*, 2011 and Vanderver *et al*, 2014                                          21         1y6m   c.A45T : p.R15S                                                                                  *de novo*     ([@b11-mco-0-0-1988],[@b14-mco-0-0-1988])
  Hansen-Kiss *et al*, 2017                                                              22         1y6m   c.G1004A : p.R335Q                                                                               Paternal      ([@b19-mco-0-0-1988])
  Varga *et al*, 2009                                                                    23         1y8m   p.T202I                                                                                          *de novo*     ([@b5-mco-0-0-1988])
  Vanderver *et al*, 2014 and Eng, 2003                                                  24         2y     c.T959G : p.L320^\*^                                                                             ND            ([@b14-mco-0-0-1988],[@b18-mco-0-0-1988])
  Hansen-Kiss *et al*, 2017                                                              25         2y     c.607_608delAT : p.L230^\*^                                                                      Maternal      ([@b19-mco-0-0-1988])
  Hansen-Kiss *et al*, 2017                                                              26         2y     c.A667T : p.K223^\*^                                                                             ND            ([@b19-mco-0-0-1988])
  Varga *et al*, 2009                                                                    27         2y3m   p.G44D                                                                                           ND            ([@b5-mco-0-0-1988])
  Butler *et al*, 2005                                                                   28         2y6m   p.F241S                                                                                          ND            ([@b20-mco-0-0-1988])
  Bhargava *et al*, 2014                                                                 29         2y7m   No protein                                                                                       ND            ([@b15-mco-0-0-1988])
  Bhargava *et al*, 2014                                                                 30         2y8m   No protein                                                                                       ND            ([@b15-mco-0-0-1988])

ND, not determined; d, days; m, months; y, years.

###### 

Clinical characteristics of 30 patients diagnosed as having PTEN mutation at \<3 years old.

                  Growth        Neurological findings   Physical features                                                                                                                                                                                                                                     
  ---- ------ --- ------------- ----------------------- -------------------------------------------------- -------------------------------------------------- ---- --------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------
  1    0d     M   \+            \+                      \+^[a](#tfn1-mco-0-0-1988){ref-type="table-fn"}^                                                           \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^                                                                                           Postaxial polydactyly
  2    3m     F   \+                                    \+^[b](#tfn2-mco-0-0-1988){ref-type="table-fn"}^                                                      \+                                                                                                                                               
  3    5m     M   \+                                    \+                                                 \+^[e](#tfn5-mco-0-0-1988){ref-type="table-fn"}^   \+   \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^    Pigmented speckled macules of the glans penis                                           
  4    7m     F   \+                                    \+                                                                                                    \+   \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^                                                                                            
  5    7m     M   \+                                    \+                                                                                                                                                             Café-au-lait spot, thyroid, nodules testicular hamartomas, rectal and gastric polyps    
  6    8m     M   \+            \+                      \+                                                                                                                                                                                                                                                     
  7    8m     M   \+ (2.8 SD)   \+                      \+                                                 \+^[f](#tfn6-mco-0-0-1988){ref-type="table-fn"}^                                                            Café-au-lait spot, subcutaneous lipomas                                                 
  8    9m     M   \+ (4.4 SD)                           \+                                                                                                                                                                                                                                                     
  9    9m     M   \+ (3.5 SD)                           \+                                                                                                         \+^[j](#tfn10-mco-0-0-1988){ref-type="table-fn"}^                                                                                           
  10   10m    F   \+                                    \+                                                                                                    \+                                                                                                                                              Abnormal EEG but no seizures
  11   10m    M   \+                                    \+^[c](#tfn3-mco-0-0-1988){ref-type="table-fn"}^                                                           \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^                                                                                            
  12   10m    F   \+                                    \+                                                                                                    \+   \+^[k](#tfn11-mco-0-0-1988){ref-type="table-fn"}^                                                                                           
  13   10m    F   \+                                    \+                                                 \+                                                 \+   \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^                                                                                           Left cataract
  14   10m    M   \+                                    \+                                                 \+^[g](#tfn7-mco-0-0-1988){ref-type="table-fn"}^                                                                                                                                                    
  15   10m    F   \+                                    \+                                                                                                         \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^    Abdomen and axillar trichilemmomas, subcutaneous lipomas                               Split uvula
  16   11m    F   \+                                    \+                                                                                                    \+                                                                                                                                               
  17   11m    F   \+                                    \+                                                                                                    \+   \+^[i](#tfn9-mco-0-0-1988){ref-type="table-fn"}^    Mucosal neuroma                                                                         
  18   1 m    M   \+                                    \+                                                                                                    \+   \+^[k](#tfn11-mco-0-0-1988){ref-type="table-fn"}^                                                                                           
  19   1y3m   F   \+                                    \+                                                                                                                                                                                                                                                     
  20   1y4m   F   \+ (5.8 SD)                           \+                                                 \+^[h](#tfn8-mco-0-0-1988){ref-type="table-fn"}^                                                                                                                                                    
  21   1y6m   M   \+                                    \+                                                                                                                                                                                                                                                     
  22   1y6m   F   \+ (2.6 SD)                           \+                                                                                                                                                             Dermalogical features, BRRS                                                            
  23   1y8m   M   \+ (6.5 SD)                           \+                                                                                                                                                                                                                                                     
  24   2y     M   \+                                    \+                                                 \+                                                 \+   \+^[l](#tfn12-mco-0-0-1988){ref-type="table-fn"}^                                                                                           
  25   2y     F   \+ (6.5 SD)                           \+                                                                                                                                                             BRRS                                                                                    
  26   2y     F   \+ (4.7 SD)                           \+                                                                                                                                                                                                                                                     
  27   2y3m   F   \+ (5.0 SD)                           \+                                                                                                                                                             Large café-au-lait spots on chest and abdomen                                          Bilateral hernia
  28   2y6m   M   \+ (4.5 SD)                           \+                                                 \+                                                                                                          Freckles on the glans penis moles, thyroid nodules, intestinal polyps                   
  29   2y7m   M   \+                                    \+                                                                                                                                                                                                                                                     
  30   2y8m   M   \+                                    \+^[d](#tfn4-mco-0-0-1988){ref-type="table-fn"}^   \+                                                                                                                                                                                                  

^a^Mild motor only at 2.5 y;

^b^diagnosed at 2 y 8 m;

^c^mild motor delay only;

^d^motor speech disorder;

^e^diagnosed at 5 y;

^f^diagnosed at 3 y 0 m;

^g^diagnosed at 3 y;

^h^diagnosed at 2 y1 m;

^i^frontal bossing;

^j^notched ears, right ear larger than left and facial asymmetry;

^k^frontal bossing and hypertelorism;

^l^frontal bossing, depressed nasal bridge, bulbous nose, and smooth philtrum. MC, macrocephaly (head circumference \>2 SD); MS, macrosomia; MR, mental retardation/developmental delay; AS, autism spectrum; BRRS, Bannayan-Riley-Ruvalcaba syndrome; d, days; m, months; y, years.
